{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e8308ce6b0fef1a38c4a215/66fa6bc3380a74ab15733c11?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"CPX-351 as first-line treatment in AML: Real-world data","description":"<p>Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment.&nbsp;&nbsp;</p>","author_name":"Scientific Education Support"}